DF
RXRX icon

Dunhill Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Dunhill Financial’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9
Closed -$28 – 1841
2026
Q1 		$28 Hold
9
– – ﹤0.01% 1721
2025
Q4 		$38 Buy
+9
New +$45 ﹤0.01% 1749

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Dunhill Financial's RXRX Position: Q2 2026 in Review

Dunhill Financial sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 9 shares — an estimated $28 sold.

Dunhill Financial first reported a position in RXRX in Q4 2025 and held it in 2 quarters. The position peaked at $38 in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Dunhill Financial reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Dunhill Financial sold 9 Recursion Pharmaceuticals shares in Q2 2026, an estimated $28.
  • Dunhill Financial first reported a position in Recursion Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Dunhill Financial's Recursion Pharmaceuticals position peaked at $38 in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.